Pharmaceuticals
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
Not intended for distribution in the USA, Canada or UK - TEPMETKO is approved for both treatment naïve and previously treated MET ex14 positive NSCLC patients - TEPMETKO demonstrated consistent and durable responses in both treatment naïve and previously treatedMETex14 patients in the VISION stud...
2021-02-04 02:57
1906
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-02-03 12:30
10199
Elekta's MOSAIQ and Versa HD earn top honors in 2021 Best in KLAS: Software and Services Report
ATLANTA, Feb. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that itsMOSAIQ® Oncology Information System (OIS) and Versa HD™ linear accelerator have been named "Best in KLAS" in the 2021 Best in KLAS: Software and Services Report. MOSAIQ was ranked first in the Oncology (Radiation) ca...
2021-02-03 00:30
3986
Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine
CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Feb. 2, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, announced today that the first healthy volunteer has been successfully dos...
2021-02-02 20:00
2227
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer
SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company recently released ...
2021-02-02 17:24
2389
Globally unique MRI Guarantee: The highest MRI safety with hearing implants from MED-EL
Worry-free, safe magnetic resonance imaging (MRI) with MED-EL cochlear, middle ear or bone conduction implants – now with lifetime guarantee. For immediate access to an MRI examination without surgery, discomfort or hearing downtime. INNSBRUCK, Austria, Feb. 2, 2021 /PRNewswire/ -- The innovative...
2021-02-02 15:00
3250
Inmagene launched U.S. subsidiary; Dr. Jean-Louis Saillot joined the company.
SAN DIEGO, Calif. and SHANGHAI, Feb. 2, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a leading biotech company focused on immunology-related therapeutic areas, today announced the launch of its wholly-owned subsidiary inSan Diego. Jean-Louis Saillot, MD has joined the company a...
2021-02-02 14:48
3350
CF PharmTech and Chengdu Shangyi Launch the "Home-Based Recovery Program for Discharged Covid-19 Patients" and Announce Today's Global Release of the "R Plus Health" Free App
SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- CF PharmTech, Inc. is a fully
integrated pharmaceutical company inChina specializing in the treatment of
respiratory diseases. Chengdu Shangyi Information Technology Co., Ltd is a
professional IT service company in the healthcare industry inChina.
2021-02-02 09:00
3794
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
* Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alumin the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. * The Coalition for Epid...
2021-02-01 14:00
6540
Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage
SHANGHAI and HONG KONG, Feb. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-02-01 08:09
5620
Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA
BEIJING and BRIDGEWATER, N.J., Jan. 29, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation fo...
2021-01-29 22:53
8745
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-01-29 20:26
7003
Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company
SUZHOU, China and ROCKVILLE, Md., Jan. 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug A...
2021-01-29 08:29
2819
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
TEL AVIV, Israel and RALEIGH, N.C., Jan. 28, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-01-28 22:03
5964
Clinical Trial of Proxalutamide's Trial of Hospitalized Covid-19 Patients Was Approved in Brazil
SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the clinical trial (the "Trial") of Proxalutamide's treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board ("IRB") ofBrazil. The trial was accept...
2021-01-28 19:57
7036
Sai Life Sciences announces plans to double headcount and expand capabilities in Manchester, UK
MANCHESTER, England and HYDERABAD, India, Jan. 28, 2021 /PRNewswire/ -- Sai
Life Sciences, one ofIndia's fastest growing Contract Research, Development &
Manufacturing Organizations
2021-01-28 15:30
3642
Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142.HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal a...
2021-01-28 12:54
8026
Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease
DUBLIN, Jan. 28, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, announced today thatJapan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft...
2021-01-28 09:00
5241
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM
SHANGHAI and HONG KONG, Jan. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...
2021-01-28 08:00
3778
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM
SHANGHAI and HONG KONG, Jan. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...
2021-01-28 08:00
5261
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 292 media titles]
2026-01-05 12:14
Novo Nordisk International Operations Commits to Veeva Vault CRM
[Picked up by 290 media titles]
2026-01-08 09:05Courtyard by Marriott Phuket, Patong Beach Resort: The Ultimate Family-Friendly Destination in 2026
[Picked up by 284 media titles]
2026-01-08 12:01
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 282 media titles]
2026-01-07 10:00
